Evidence map›Paper›PMID 39358603›Full record

ArticleEMBO molecular medicine2024

A new class of capsid-targeting inhibitors that specifically block HIV-1 nuclear import.

Aude Boulay, Emmanuel Quevarec, Isabelle Malet, Giuseppe Nicastro, Célia Chamontin, Suzon Perrin, Corinne Henriquet, Martine Pugnière, Valérie Courgnaud, Mickaël Blaise and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aude BoulayInstitut de Recherche en Infectiologie de Montpellier (IRIM), University of Montpellier, CNRS 9004, 34293, Montpellier, France.
Emmanuel QuevarecInstitut de Recherche en Infectiologie de Montpellier (IRIM), University of Montpellier, CNRS 9004, 34293, Montpellier, France.
Isabelle MaletDepartment of Virology, INSERM, Sorbonne University, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
Giuseppe NicastroMacromolecular Structure Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.ORCID http://orcid.org/0000-0002-7857-8983
Célia ChamontinInstitut de Recherche en Infectiologie de Montpellier (IRIM), University of Montpellier, CNRS 9004, 34293, Montpellier, France.ORCID http://orcid.org/0000-0001-7760-373X
Suzon PerrinInstitut de Recherche en Infectiologie de Montpellier (IRIM), University of Montpellier, CNRS 9004, 34293, Montpellier, France.
Corinne HenriquetInstitut de Recherche en Cancérologie de Montpellier, INSERM, University of Montpellier, Institut Régional du Cancer, Montpellier, France.
Martine PugnièreInstitut de Recherche en Cancérologie de Montpellier, INSERM, University of Montpellier, Institut Régional du Cancer, Montpellier, France.
Valérie CourgnaudRNA viruses and host factors, Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS-UMR 5535, 1919 Route de Mende, Montpellier, 34293, Cedex 5, France.
Mickaël BlaiseInstitut de Recherche en Infectiologie de Montpellier (IRIM), University of Montpellier, CNRS 9004, 34293, Montpellier, France.ORCID http://orcid.org/0000-0002-7860-3464
Anne-Geneviève MarcelinDepartment of Virology, INSERM, Sorbonne University, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
Ian A TaylorMacromolecular Structure Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.ORCID http://orcid.org/0000-0002-6763-3852
Laurent ChaloinInstitut de Recherche en Infectiologie de Montpellier (IRIM), University of Montpellier, CNRS 9004, 34293, Montpellier, France.ORCID http://orcid.org/0000-0002-5757-5804
Nathalie J ArhelInstitut de Recherche en Infectiologie de Montpellier (IRIM), University of Montpellier, CNRS 9004, 34293, Montpellier, France. nathalie.arhel@irim.cnrs.fr.ORCID http://orcid.org/0000-0001-5309-1725

Funding

Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) ECTZ209411BIOLuM 2021Montpellier Université d'Excellence (MUSE) iSiteSidaction AAP31-1-AEQ-12643Wellcome Trust CC1078Wellcome Trust CC2029
6 · The paper itself

Abstract

HIV-1 capsids cross nuclear pore complexes (NPCs) by engaging with the nuclear import machinery. To identify compounds that inhibit HIV-1 nuclear import, we screened drugs in silico on a three-dimensional model of a CA hexamer bound by Transportin-1 (TRN-1). Among hits, compound H27 inhibited HIV-1 with a low micromolar IC

Indexed as

Active Transport, Cell NucleusAnti-HIV AgentsCapsidHIV-1AnimalsCapsid ProteinsDrug Evaluation, PreclinicalHIV InfectionsHumansModels, MolecularAnti-HIV AgentsCapsid ProteinsAntiretroviral TherapyCapsidDrug DiscoveryHIV-1Nuclear Import

Identifiers

PMID39358603
PMCPMC11555092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.